Patents by Inventor Manami Ohnuma

Manami Ohnuma has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Method for screening agonist or antagonist of the maxadilan receptor participating in vasodilating action, and compound found by the method
    Patent number: 6462016
    Abstract: There are provided a method to screen agonist or antagonist of the maxadilan receptor participating in vasodilating action, wherein a receptor of maxadilan is used, compounds which specifically bind to the receptor, and a tissue preparation having the receptor. The compounds are variants of maxadilan from the salivary glands of the sand fly.
    Type: Grant
    Filed: November 13, 1997
    Date of Patent: October 8, 2002
    Assignees: Shiseido Company, Ltd., The General Hospital Corporation
    Inventors: Kawori Wakita, Osamu Moro, Manami Ohnuma, Ethan A. Lerner, Masahiro Tajima
  • Peptides having specific affinity to pituitary adenylate cyclase activating polypeptide type 1 receptors
    Patent number: 6017533
    Abstract: This specification relates to the use of peptides having a specific affinity to pituitary adenylate cyclase activating polypeptide (PACAP) receptors, particularly MAX (67 amino acids), NSP (61 amino acids) and M65 (46 amino acids). MAX and NSP act as agonists to PACAP type 1 receptors, and M65 acts as an antagonist to PACAP type 1 receptors.
    Type: Grant
    Filed: April 25, 1996
    Date of Patent: January 25, 2000
    Assignees: Shiseido Company, Ltd., The General Hospital Corporation
    Inventors: Osamu Moro, Kawori Wakita, Manami Ohnuma, Ethan A. Lerner, Masahiro Tajima
  • External preparation for skin
    Patent number: 5690914
    Abstract: An external preparation for skin including one or more than two types of tranexamic acid derivatives represented by the following general formula (A). GENERAL FORMULA (A) ##STR1## (In the formula (A), R.sub.1, R.sub.2 and R.sub.3 represents hydrogen atoms or substituents and at least one of these is the substituent.) The external preparation for skin including the derivatives have excellent depigmentation effect as well as skin care effect.
    Type: Grant
    Filed: August 27, 1993
    Date of Patent: November 25, 1997
    Assignee: Shiseido Co., Ltd
    Inventors: Masaru Suetsugu, Manami Ohnuma, Yoshihiro Morikawa, Yuki Yamase, Naoe Akiyama, Kenji Kitamura
  • Modified maxadilan protein, its preparation and use, and DNA encoding the protein
    Patent number: 5480864
    Abstract: A modified maxadilan protein exhibits higher biological activity than native maxadilan from the sand fly Lutzomyia longipalpis. A modified maxadilan fusion protein contains a thrombin cleavage site. This enables the production of the modified maxadilan as a fusion protein and recovery of the modified maxadilan after digestion with thrombin. The modified maxadilan is a potent vasodilator.
    Type: Grant
    Filed: August 6, 1993
    Date of Patent: January 2, 1996
    Assignees: Shiseido Co., Ltd., The General Hospital
    Inventors: Masahiro Tajima, Manami Ohnuma, Ethan L. Lerner